Literature DB >> 31339086

Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature.

Michael D Banov1,2, Jonathan R Young3, Tyler Dunn1, Steven T Szabo3,4.   

Abstract

Anxiety disorders are among the most prevalent psychiatric conditions. Despite many proven pharmacological and non-pharmacological treatments available, high rates of partial response and low rates of long-term remission remain. Ketamine has been receiving increasing attention as an interventional treatment modality in psychiatry, especially among refractory conditions, including major depressive disorder. There is limited yet growing evidence to support the use of ketamine in anxiety disorders. In this review of the literature, we present case reports, case series, and controlled trials demonstrating proof-of-concept for its potential role in the treatment of anxiety and anxiety spectrum disorders. Its unique mechanism of action, rapid onset, and high rate of response have driven its use in clinical practice. Ketamine is generally well tolerated by patients and has a limited side effect profile; however, the effects of long-term use are unknown. While there is a growing body of research and increasing clinical experience to suggest ketamine may have clinical applications in the treatment of refractory anxiety disorders, further research to determine long-term safety and tolerability is indicated.

Entities:  

Keywords:  GAD; Ketamine; OCD; PTSD; anxiety; generalized anxiety disorder; panic disorder; social anxiety disorder

Year:  2019        PMID: 31339086     DOI: 10.1017/S1092852919001238

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  7 in total

1.  Increased signal diversity/complexity of spontaneous EEG, but not evoked EEG responses, in ketamine-induced psychedelic state in humans.

Authors:  Nadine Farnes; Bjørn E Juel; André S Nilsen; Luis G Romundstad; Johan F Storm
Journal:  PLoS One       Date:  2020-11-23       Impact factor: 3.240

Review 2.  Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology.

Authors:  Madeeha Nasir; Daniel Trujillo; Jessica Levine; Jennifer B Dwyer; Zachary W Rupp; Michael H Bloch
Journal:  Front Psychiatry       Date:  2020-11-19       Impact factor: 4.157

Review 3.  A Novel Application of Ketamine for Improving Perioperative Sleep Disturbances.

Authors:  Bijia Song; Junchao Zhu
Journal:  Nat Sci Sleep       Date:  2021-12-25

4.  Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders.

Authors:  Elizabeth Whittaker; Alisher R Dadabayev; Sonalee A Joshi; Paul Glue
Journal:  Ther Adv Psychopharmacol       Date:  2021-12-15

Review 5.  Clinical Uses of Ketamine in Children: A Narrative Review.

Authors:  Anoushka Bali; Ashujot Kaur Dang; Daniel A Gonzalez; Rajeswar Kumar; Saba Asif
Journal:  Cureus       Date:  2022-07-20

Review 6.  Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease.

Authors:  Deborah J Luessen; P Jeffrey Conn
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

Review 7.  Ketamine treatment for refractory anxiety: A systematic review.

Authors:  Jamie L Tully; Amelia D Dahlén; Connor J Haggarty; Helgi B Schiöth; Samantha Brooks
Journal:  Br J Clin Pharmacol       Date:  2022-05-20       Impact factor: 3.716

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.